Danish pharmaceutical firm H. Lundbeck A/S Wednesday reported a loss for the second quarter of 2012, as restructuring costs and its key Lexapro drugs patent expired in the U.S., yet Lundbeck maintained its full-year guidance and said new drugs launched will compensate for the drop in Lexapro sales. Lundbeck said it still expects full-year 2012 sales to come in between 14.5 billion Danish kroner ($2.42 billion) and DKK15.2 billion, and earnings before interest and tax, or EBIT, to fall to between DKK2.0 billion and DKK2.5 billion. 2012 Ebitda is seen at DKK3.0 billion to DKK3.5 billion, also unchanged from the previous guidance announcement.
